Tamar Taddei, MD
Research & Publications
Biography
News
Research Summary
Dr. Taddei has built clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with liver cancer. In 2009, she developed the VA Connecticut Liver Tumor Board, now a regional tumor board serving VA Medical Centers in Connecticut, Rhode Island, Massachusetts, and Vermont. In 2011, she oversaw the accreditation of the Yale Liver Tumor Board, approved by the Smilow Cancer Hospital at Yale New Haven's Cancer Committee to meet all requirements of accreditation by the American College of Surgeons. She has been funded by the VA National Center for Patient Safety and the VA Office of HIV, Hepatitis and Related Conditions Programs for national implementation of the Coordinated Care Tracking System, a locally developed tool to improve liver cancer detection and comprehensive care. She is co-Principal Investigator of the Veteran's Outcomes and Costs Associated with Liver disease (VOCAL) study group, a national VA research consortium studying outcomes in Veterans with cirrhosis and liver cancer. She is co-Principal Investigator of the VA Clinical Science Research and Development (CSR&D)-funded randomized controlled trial of Statins in Cirrhosis - Reducing Events of Decompensation (SACRED). She is co-Chair of the VA Cooperative Studies Program (CSP)-funded randomized liver cancer screening trial, PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM).
She collaborates on several translational projects that seek to understand the biology of liver cancer to inform prognosis and targets for treatment. She mentors trainees in research and considers this one of the most important and gratifying aspects of her career.
Specialized Terms: Clinical, translational, and outcome research on hepatocellular carcinoma
Coauthors
Research Interests
Delivery of Health Care; Digestive System Diseases; Carcinoma, Hepatocellular; Liver Cirrhosis; Translational Research, Biomedical
Public Health Interests
Health Care Quality, Efficiency; Health Care Management
Selected Publications
- The Association Between Homelessness and Key Liver-Related Outcomes in Veterans With CirrhosisPulaski M, Bittermann T, Taddei T, Kaplan D, Mahmud N. The Association Between Homelessness and Key Liver-Related Outcomes in Veterans With Cirrhosis. The American Journal Of Gastroenterology 2023, 119: 297-305. PMID: 37782293, DOI: 10.14309/ajg.0000000000002535.
- Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascitesChin A, Bastaich D, Dahman B, Kaplan D, Taddei T, John B. Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites. Hepatology 2023, 79: 844-856. PMID: 37625139, DOI: 10.1097/hep.0000000000000577.
- Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement ProjectRogal S, Taddei T, Monto A, Yakovchenko V, Patton H, Merante M, Spoutz P, Chia L, Yudkevich J, Aytaman A, Rabiee A, John B, Blechacz B, Cai C, Gilles H, Shah A, McCurdy H, Puri P, Jou J, Mazhar K, Dominitz J, Anwar J, Morgan T, Ioannou G. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology And Hepatology 2023, 22: 324-338. PMID: 37460005, PMCID: PMC10788380, DOI: 10.1016/j.cgh.2023.07.002.
- Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIVTorgersen J, Akers S, Huo Y, Terry J, Carr J, Ruutiainen A, Skanderson M, Levin W, Lim J, Taddei T, So‐Armah K, Bhattacharya D, Rentsch C, Shen L, Carr R, Shinohara R, McClain M, Freiberg M, Justice A, Re V. Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV. Pharmacoepidemiology And Drug Safety 2023, 32: 1121-1130. PMID: 37276449, PMCID: PMC10527049, DOI: 10.1002/pds.5648.
- Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular CarcinomaCao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.
- The role of routine biopsy of the background liver in the management of hepatocellular carcinomaLee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.
- Multidisciplinary teams, efficient communication, procedure services, and telehealth improve cirrhosis care: A qualitative studySerper M, Agha A, Garren P, Taddei T, Kaplan D, Groeneveld P, Werner R, Shea J. Multidisciplinary teams, efficient communication, procedure services, and telehealth improve cirrhosis care: A qualitative study. Hepatology Communications 2023, 7: e0157. PMID: 37219845, PMCID: PMC10208700, DOI: 10.1097/hc9.0000000000000157.
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinomaSingal A, Llovet J, Yarchoan M, Mehta N, Heimbach J, Dawson L, Jou J, Kulik L, Agopian V, Marrero J, Mendiratta-Lala M, Brown D, Rilling W, Goyal L, Wei A, Taddei T. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023, 78: 1922-1965. PMID: 37199193, PMCID: PMC10663390, DOI: 10.1097/hep.0000000000000466.
- Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosisJohn B, Bastaich D, Webb G, Brevini T, Moon A, Ferreira R, Chin A, Kaplan D, Taddei T, Serper M, Mahmud N, Deng Y, Chao H, Sampaziotis F, Dahman B. Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis. Journal Of Internal Medicine 2023, 293: 636-647. PMID: 37018129, DOI: 10.1111/joim.13630.
- The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort studyShaffer L, Kaplan D, Taddei T, Mahmud N. The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort study. Hepatology Communications 2023, 7: e0129. PMID: 36996031, PMCID: PMC10069831, DOI: 10.1097/hc9.0000000000000129.
- Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosisRabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.
- Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failureChapin S, Kaplan D, Taddei T, Mahmud N. Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure. JHEP Reports 2023, 5: 100740. PMID: 37215188, PMCID: PMC10193237, DOI: 10.1016/j.jhepr.2023.100740.
- Enhanced Identification of Hispanic Ethnicity Using Clinical DataOchoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.
- The risk of hepatocellular carcinoma is markedly increased in Gaucher diseaseBasiri M, Ruan J, Nair S, Lau H, Mistry P, Taddei T. The risk of hepatocellular carcinoma is markedly increased in Gaucher disease. Molecular Genetics And Metabolism 2023, 138: 107022. DOI: 10.1016/j.ymgme.2022.107022.
- When to Stop Screening—Liver CancerTaddei T, Jou J. When to Stop Screening—Liver Cancer. The American Journal Of Gastroenterology 2022, 118: 427-428. PMID: 36563304, DOI: 10.14309/ajg.0000000000002120.
- Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCCJaffe A, Taddei T, Giannini E, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC. Liver International 2022, 43: 258-259. PMID: 36426717, DOI: 10.1111/liv.15482.
- “Am I Going to Die?”: Delivering Serious News to Patients With Liver DiseasePatel A, Arnold R, Taddei T, Woodrell C. “Am I Going to Die?”: Delivering Serious News to Patients With Liver Disease. Gastroenterology 2022, 164: 177-181. PMID: 36379246, PMCID: PMC10662545, DOI: 10.1053/j.gastro.2022.11.006.
- Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort studySerper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2022, 77: 489-500. PMID: 35984731, PMCID: PMC9877112, DOI: 10.1002/hep.32737.
- Attacking the public health crisis of hepatocellular carcinoma at its rootsLee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.
- Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbookJaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.
- COVID-19 and the liver: a narrative review of the present state of knowledgeThandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.
- Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosisJohn BV, Ferreira RD, Doshi A, Kaplan DE, Taddei TH, Spector SA, Paulus E, Deng Y, Bastaich D, Dahman B. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal Of Hepatology 2022, 77: 1349-1358. PMID: 36181987, PMCID: PMC9519143, DOI: 10.1016/j.jhep.2022.07.036.
- Type of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration StudyMahmud N, Reddy KR, Taddei TH, Kaplan DE. Type of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration Study. Digestive Diseases And Sciences 2022, 68: 1632-1640. PMID: 36083379, PMCID: PMC9995592, DOI: 10.1007/s10620-022-07680-9.
- Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the PandemicSerper M, Tapper EB, Kaplan DE, Taddei TH, Mahmud N. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American Journal Of Gastroenterology 2022, 118: 294-303. PMID: 36114778, PMCID: PMC9898115, DOI: 10.14309/ajg.0000000000002011.
- COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosisJohn B, Bastaich D, Ferreira R, Doshi A, Taddei T, Kaplan D, Spector S, Deng Y, Dahman B. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis. Gut 2022, 72: 1800-1802. PMID: 36562753, DOI: 10.1136/gutjnl-2022-327799.
- Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination toolZhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Ciarleglio M, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose M, Taddei T. Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool. PLOS Digital Health 2022, 1: e0000080. PMID: 36812575, PMCID: PMC9931271, DOI: 10.1371/journal.pdig.0000080.
- Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosisJohn BV, Doshi A, Ferreira RD, Taddei TH, Kaplan DE, Spector SA, Deng Y, Bastaich D, Dahman B. Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis. Hepatology 2022, 77: 186-196. PMID: 35712794, DOI: 10.1002/hep.32619.
- THU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosisJohn B, Doshi A, Deng Y, Mansour N, Barritt A, Moon A, Ioannou G, Martin P, Chao H, Taddei T, Kaplan D, Dahman B. THU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis. Journal Of Hepatology 2022, 77: s223. PMCID: PMC9252350, DOI: 10.1016/s0168-8278(22)00818-2.
- Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosisJohn BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao H, Dahman B. Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022, 76: 126-138. PMID: 35023206, PMCID: PMC9015228, DOI: 10.1002/hep.32337.
- Using Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular CarcinomaChoi DT, Sada YH, Sansgiry S, Kaplan DE, Taddei TH, Aguilar JK, Strayhorn M, Hernaez R, Davila JA. Using Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular Carcinoma. Journal Of Gastrointestinal Cancer 2022, 54: 623-631. PMID: 35773376, PMCID: PMC9247952, DOI: 10.1007/s12029-022-00844-w.
- Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in CirrhosisJohn BV, Barritt A, Moon A, Taddei TH, Kaplan DE, Dahman B, , Doshi A, Deng Y, Mansour N, Ioannou G, Martin P, Chao H. Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastroenterology And Hepatology 2022, 20: 2405-2408.e3. PMID: 35716904, PMCID: PMC9212810, DOI: 10.1016/j.cgh.2022.05.038.
- Diagnostic Momentum in Acute Liver Injury: an Exercise in Clinical ReasoningThomas I, Roberts A, Sharma S, Penner J, Taddei T. Diagnostic Momentum in Acute Liver Injury: an Exercise in Clinical Reasoning. Journal Of General Internal Medicine 2022, 37: 2861-2865. PMID: 35676586, PMCID: PMC9411385, DOI: 10.1007/s11606-022-07673-4.
- Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver DiseasesAsrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El‐Serag H, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022, 75: 1289-1299. PMID: 34778999, DOI: 10.1002/hep.32240.
- MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic FeaturesPetukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin M, Kucukkaya AS, Gottwald LA, Gebauer B, Revzin M, Onofrey J, Staib L, Gunabushanam G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal Of Vascular And Interventional Radiology 2022, 33: 814-824.e3. PMID: 35460887, PMCID: PMC9335926, DOI: 10.1016/j.jvir.2022.04.006.
- Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.
- The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort StudyMahmud N, Serper M, Taddei TH, Kaplan DE. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology 2022, 163: 257-269.e6. PMID: 35398042, PMCID: PMC10020994, DOI: 10.1053/j.gastro.2022.03.052.
- Palliative Care Always: Hepatology—Virtual Primary Palliative Care Training for HepatologistsDeNofrio JC, Verma M, Kosinski AS, Navarro V, Taddei TH, Volk ML, Bakitas M, Ramchandran K. Palliative Care Always: Hepatology—Virtual Primary Palliative Care Training for Hepatologists. Hepatology Communications 2022, 6: 920-930. PMID: 34719137, PMCID: PMC8948550, DOI: 10.1002/hep4.1849.
- Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”Torgersen J, Taddei TH, Lo Re V. Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”. Journal Of Hepatology 2022, 77: 258-259. PMID: 35283213, DOI: 10.1016/j.jhep.2022.02.025.
- Clinical Research Training During Gastroenterology FellowshipSaffo S, Taddei T. Clinical Research Training During Gastroenterology Fellowship. Digestive Diseases And Sciences 2022, 67: 1097-1100. PMID: 35113277, PMCID: PMC8983466, DOI: 10.1007/s10620-022-07407-w.
- Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohortMahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.
- Oral Cyanobacteria and hepatocellular carcinomaHernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and hepatocellular carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0804-a.2021. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.
- Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort studyHowell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.
- Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health SystemJohn BV, Schwartz K, Scheinberg AR, Dahman B, Spector S, Deng Y, Goldberg D, Martin P, Taddei TH, Kaplan DE. Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. Transplantation 2021, 106: 72-84. PMID: 33587434, PMCID: PMC8239056, DOI: 10.1097/tp.0000000000003615.
- Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association studyWang Z, Budhu AS, Shen Y, Wong LL, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao H, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang H, Lee M, Huang Y, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas CE, Yuan J, Khor CC, Koh W, Risch H, Wang XW, Yu H. Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study. JGH Open 2021, 5: 1363-1372. PMID: 34950780, PMCID: PMC8674550, DOI: 10.1002/jgh3.12682.
- Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant RecipientsJohn BV, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Dahman B. Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. Gastroenterology 2021, 162: 645-647.e2. PMID: 34758352, PMCID: PMC8572555, DOI: 10.1053/j.gastro.2021.11.001.
- Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosisJohn BV, Dahman B, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Levy C. Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis. Liver International 2021, 42: 384-393. PMID: 34614294, PMCID: PMC8810619, DOI: 10.1111/liv.15079.
- Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With CirrhosisJohn BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.
- Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year ExperienceRabiee A, Taddei T, Aytaman A, Rogal SS, Kaplan DE, Morgan TR. Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. Cancers 2021, 13: 4849. PMID: 34638333, PMCID: PMC8508370, DOI: 10.3390/cancers13194849.
- Hepatocellular CarcinomaJain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, DOI: 10.1093/ajcp/aqab125.
- Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National CohortsSerper M, Kaplan DE, Lin M, Taddei TH, Parikh ND, Werner RM, Tapper EB. Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. Digestive Diseases And Sciences 2021, 67: 2094-2104. PMID: 34374917, PMCID: PMC10849043, DOI: 10.1007/s10620-021-07150-8.
- Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and CirrhosisJohn BV, Schwartz K, Levy C, Dahman B, Deng Y, Martin P, Taddei TH, Kaplan DE. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology Communications 2021, 5: 1426-1436. PMID: 34430786, PMCID: PMC8369937, DOI: 10.1002/hep4.1720.
- Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and CirrhosisJohn BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.
- Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensationTorgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.
- Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metforminSaffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.
- The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinomaSellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine 2021, 10: 5395-5404. PMID: 34318618, PMCID: PMC8366096, DOI: 10.1002/cam4.3573.
- Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort StudyMahmud N, Fricker Z, Lewis JD, Taddei TH, Goldberg DS, Kaplan DE. Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Clinical Gastroenterology And Hepatology 2021, 20: e1121-e1134. PMID: 34246794, PMCID: PMC8741885, DOI: 10.1016/j.cgh.2021.06.050.
- Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver DiseaseKanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.
- HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.Patil PA, Taddei T, Jain D, Zhang X. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 146: 220-226. PMID: 34086854, DOI: 10.5858/arpa.2020-0725-oa.
- Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated CirrhosisJohn BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.
- Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major SurgeriesMahmud N, Kaplan DE, Taddei TH, Goldberg DS. Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transplantation 2021, 27: 699-710. PMID: 33226691, PMCID: PMC8517916, DOI: 10.1002/lt.25953.
- Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal AdenocarcinomaSaffo S, Peng C, Salem R, Taddei T, Nagar A. Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. Digestive Diseases And Sciences 2021, 67: 1409-1416. PMID: 33811566, PMCID: PMC8487432, DOI: 10.1007/s10620-021-06967-7.
- Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with CirrhosisMahmud N, Asrani SK, Reese PP, Kaplan DE, Taddei TH, Nadim MK, Serper M. Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. Digestive Diseases And Sciences 2021, 67: 1399-1408. PMID: 33761091, PMCID: PMC8460692, DOI: 10.1007/s10620-021-06943-1.
- SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of DecompensationKaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.
- Advance Care Planning: A Convincing Argument to Make It Part of Liver Transplant EvaluationVerma M, Taddei T, Volk M, Navarro V. Advance Care Planning: A Convincing Argument to Make It Part of Liver Transplant Evaluation. Liver Transplantation 2021, 27: 461-462. PMID: 32978855, DOI: 10.1002/lt.25901.
- The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis CohortMahmud N, Asrani SK, Kaplan DE, Ogola GO, Taddei TH, Kamath PS, Serper M. The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort. Liver Transplantation 2021, 27: 177-189. PMID: 33025731, PMCID: PMC7880877, DOI: 10.1002/lt.25913.
- Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.
- Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 PandemicMahmud N, Kaplan DE, Goldberg DS, Taddei TH, Serper M. Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology 2021, 160: 2162-2164.e3. PMID: 33434604, PMCID: PMC8142896, DOI: 10.1053/j.gastro.2021.01.007.
- Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With AnticoagulationSerper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology 2021, 73: 219-232. PMID: 32267547, PMCID: PMC7541418, DOI: 10.1002/hep.31264.
- Risk Prediction Models for Post‐Operative Mortality in Patients With CirrhosisMahmud N, Fricker Z, Hubbard RA, Ioannou GN, Lewis JD, Taddei TH, Rothstein KD, Serper M, Goldberg DS, Kaplan DE. Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis. Hepatology 2021, 73: 204-218. PMID: 32939786, PMCID: PMC7902392, DOI: 10.1002/hep.31558.
- Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute‐on‐Chronic Liver FailureShah S, Goldberg DS, Kaplan DE, Sundaram V, Taddei TH, Mahmud N. Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute‐on‐Chronic Liver Failure. Liver Transplantation 2021, 27: 16-26. PMID: 32946660, PMCID: PMC8249075, DOI: 10.1002/lt.25896.
- Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 530-534. PMID: 33185999, PMCID: PMC8353543, DOI: 10.1097/qai.0000000000002510.
- SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertensionSaffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.
- AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert ReviewTandon P, Walling A, Patton H, Taddei T. AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert Review. Clinical Gastroenterology And Hepatology 2020, 19: 646-656.e3. PMID: 33221550, DOI: 10.1016/j.cgh.2020.11.027.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal Of Clinical Oncology 2020, 38: 4317-4345. PMID: 33197225, DOI: 10.1200/jco.20.02672.
- Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for VeteransRogal SS, Yakovchenko V, Morgan T, Bajaj JS, Gonzalez R, Park A, Beste L, Miech EJ, Lamorte C, Neely B, Gibson S, Malone PS, Chartier M, Taddei T, Garcia-Tsao G, Powell BJ, Dominitz JA, Ross D, Chinman MJ. Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. Implementation Science 2020, 15: 92. PMID: 33087156, PMCID: PMC7579930, DOI: 10.1186/s13012-020-01050-7.
- Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort studyHajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.
- Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort studyRentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re V, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLOS Medicine 2020, 17: e1003379. PMID: 32960880, PMCID: PMC7508372, DOI: 10.1371/journal.pmed.1003379.
- Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives Of Pathology & Laboratory Medicine 2020, 145: 419-427. PMID: 32810870, PMCID: PMC10960369, DOI: 10.5858/arpa.2020-0008-oa.
- Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and CirrhosisKaplan DE, Serper M, John BV, Tessiatore KM, Lerer R, Mehta R, Fox R, Aytaman A, Baytarian M, Hunt K, Albrecht J, Taddei TH, Group V. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. Clinical Gastroenterology And Hepatology 2020, 19: 2148-2160.e14. PMID: 32798709, DOI: 10.1016/j.cgh.2020.08.026.
- Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 FailureMahmud N, Sundaram V, Kaplan DE, Taddei TH, Goldberg DS. Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. Hepatology 2020, 72: 230-239. PMID: 31677284, PMCID: PMC7195222, DOI: 10.1002/hep.31012.
- Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular CarcinomaZhang Y, Weinreb J, Czeyda-Pommersheim F, Taddei T. Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular Carcinoma. Journal Of The American College Of Radiology 2020, 17: 1636-1643. PMID: 32533924, DOI: 10.1016/j.jacr.2020.05.003.
- Models for acute on chronic liver failure development and mortality in a veterans affairs cohortXiao KY, Hubbard RA, Kaplan DE, Taddei TH, Goldberg DS, Mahmud N. Models for acute on chronic liver failure development and mortality in a veterans affairs cohort. Hepatology International 2020, 14: 587-596. PMID: 32519219, PMCID: PMC7656856, DOI: 10.1007/s12072-020-10060-y.
- An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.
- Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlationTefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.
- Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting AntiviralsDo A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.
- Palliative Care in Cirrhosis: Beyond MisconceptionsJakab S, Verma M, Navarro V, Taddei T. Palliative Care in Cirrhosis: Beyond Misconceptions. Current Treatment Options In Gastroenterology 2020, 18: 245-254. DOI: 10.1007/s11938-020-00283-1.
- Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control studyShen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study. Cancer Causes & Control 2020, 31: 321-332. PMID: 32060838, PMCID: PMC7136513, DOI: 10.1007/s10552-020-01277-1.
- Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma.Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020, 104: 104-112. PMID: 31283688, PMCID: PMC6928443, DOI: 10.1097/tp.0000000000002816.
- Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular CarcinomaTorgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.
- Risk prediction scores for acute on chronic liver failure development and mortalityMahmud N, Hubbard RA, Kaplan DE, Taddei TH, Goldberg DS. Risk prediction scores for acute on chronic liver failure development and mortality. Liver International 2019, 40: 1159-1167. PMID: 31840390, PMCID: PMC7371261, DOI: 10.1111/liv.14328.
- Quality Measures, All‐Cause Mortality, and Health Care Use in a National Cohort of Veterans With CirrhosisSerper M, Kaplan DE, Shults J, Reese PP, Beste LA, Taddei TH, Werner RM. Quality Measures, All‐Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. Hepatology 2019, 70: 2062-2074. PMID: 31107967, PMCID: PMC6864236, DOI: 10.1002/hep.30779.
- Analysis of weekend effect in severe acute liver injury: A nationwide database studyDo A, Ilagan‐Ying Y, Taddei TH. Analysis of weekend effect in severe acute liver injury: A nationwide database study. Health Science Reports 2019, 3: e139. PMID: 32166187, PMCID: PMC7060892, DOI: 10.1002/hsr2.139.
- HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.
- Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling studyUyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLOS ONE 2019, 14: e0221614. PMID: 31449554, PMCID: PMC6709904, DOI: 10.1371/journal.pone.0221614.
- The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insuranceSellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Medicine 2019, 8: 5948-5958. PMID: 31436905, PMCID: PMC6792508, DOI: 10.1002/cam4.2251.
- Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled TrialVerma M, Kosinski AS, Volk ML, Taddei T, Ramchandran K, Bakitas M, Green K, Green L, Navarro V. Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial. Journal Of Palliative Medicine 2019, 22: s-34-s-43. PMID: 31486722, DOI: 10.1089/jpm.2019.0121.
- Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 ScoresIoannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019, 157: 1264-1278.e4. PMID: 31356807, PMCID: PMC6815714, DOI: 10.1053/j.gastro.2019.07.033.
- Macrotrabecular Hepatocellular CarcinomaJeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.
- Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortalityMahmud N, John B, Taddei T, Goldberg DS. Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality. Clinical Transplantation 2019, 33: e13634. PMID: 31177570, PMCID: PMC6635076, DOI: 10.1111/ctr.13634.
- Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated CirrhosisMahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology 2019, 69: 2150-2163. PMID: 30615211, PMCID: PMC6461492, DOI: 10.1002/hep.30494.
- Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis BFox RK, Taddei TH, Kaplan DE. Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B. JAMA Internal Medicine 2019, 179: 640-641. PMID: 30882884, DOI: 10.1001/jamainternmed.2018.8314.
- Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected peopleTorgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V. Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. BMC Gastroenterology 2019, 19: 52. PMID: 30987601, PMCID: PMC6466708, DOI: 10.1186/s12876-019-0969-1.
- Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C VirusNjei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.
- Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment StrategiesSaffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases And Sciences 2019, 64: 1016-1029. PMID: 30887150, DOI: 10.1007/s10620-019-05582-x.
- Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With CirrhosisKaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH, Group V. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019, 156: 1693-1706.e12. PMID: 30660733, DOI: 10.1053/j.gastro.2019.01.026.
- Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular PearlsCostantino A, Taddei T. Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls. Current Hepatology Reports 2018, 17: 412-424. DOI: 10.1007/s11901-018-0426-6.
- Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1Schuette D, Moore LM, Robert ME, Taddei TH, Ehrlich BE. Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers & Prevention 2018, 27: cebp.0167.2018. PMID: 29789326, PMCID: PMC8465775, DOI: 10.1158/1055-9965.epi-18-0167.
- SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascitesSaffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clinical Liver Disease 2018, 11: 141-144. PMID: 30992805, PMCID: PMC6385962, DOI: 10.1002/cld.714.
- Implementation of a Population-Based Cirrhosis Identification and Management SystemKanwal F, Mapaskhi S, Smith D, Taddei T, Hussain K, Madu S, Duong N, White D, Cao Y, Mehta R, El-Serag H, Asch S, Midboe A. Implementation of a Population-Based Cirrhosis Identification and Management System. Clinical Gastroenterology And Hepatology 2018, 16: 1182-1186.e2. PMID: 29803805, PMCID: PMC7185902, DOI: 10.1016/j.cgh.2018.01.041.
- Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity MatchingKaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.
- Comparison of Natural Language Processing and Manual Coding for the Identification of Cross-Sectional Imaging Reports Suspicious for Lung CancerWadia R, Akgun K, Brandt C, Fenton BT, Levin W, Marple AH, Garla V, Rose MG, Taddei T, Taylor C. Comparison of Natural Language Processing and Manual Coding for the Identification of Cross-Sectional Imaging Reports Suspicious for Lung Cancer. JCO Clinical Cancer Informatics 2018, 2: 1-7. PMID: 30652545, PMCID: PMC6873962, DOI: 10.1200/cci.17.00069.
- Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy.Zhang Y, Arango J, Weinreb J, Taddei T. Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy. Journal Of Clinical Oncology 2018, 36: 259-259. DOI: 10.1200/jco.2018.36.4_suppl.259.
- The effect of socioeconomic factors on the outcome of hepatocellular carcinoma.Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.
- Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinomaKaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.
- Palliative care in decompensated cirrhosis: A reviewLangberg KM, Kapo JM, Taddei TH. Palliative care in decompensated cirrhosis: A review. Liver International 2018, 38: 768-775. PMID: 29112338, DOI: 10.1111/liv.13620.
- Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional StudyReiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal Of Clinical Oncology 2017, 35: jco.2017.73.824. PMID: 28872925, PMCID: PMC5662845, DOI: 10.1200/jco.2017.73.8245.
- Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United StatesKaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.
- A Clinical Decision Support System for Monitoring Post-Colonoscopy Patient Follow-Up and Scheduling.Wadia R, Shifman M, Levin FL, Marenco L, Brandt CA, Cheung KH, Taddei T, Krauthammer M. A Clinical Decision Support System for Monitoring Post-Colonoscopy Patient Follow-Up and Scheduling. AMIA Joint Summits On Translational Science Proceedings 2017, 2017: 295-301. PMID: 28815144, PMCID: PMC5543375.
- Pursuing a Gastroenterology Fellowship as a Foreign Medical GraduateNjei B, Taddei TH. Pursuing a Gastroenterology Fellowship as a Foreign Medical Graduate. Digestive Diseases And Sciences 2017, 62: 1852-1854. PMID: 28555326, DOI: 10.1007/s10620-017-4624-9.
- Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVESButt AA, Ren Y, Re V, Taddei T, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clinical Infectious Diseases 2017, 65: 64-72. PMID: 28369305, DOI: 10.1093/cid/cix224.
- Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain disseminationVilarinho S, Erson-Omay E, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH. Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. Journal Of Hepatology 2017, 67: 186-191. PMID: 28323122, PMCID: PMC5497691, DOI: 10.1016/j.jhep.2017.03.009.
- Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and MortalitySerper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.
- Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosisGoldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama A, Kaplan DE. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 2017, 65: 864-874. PMID: 27531119, DOI: 10.1002/hep.28765.
- Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.
- Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.
- Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.
- Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosisLangberg KM, Taddei TH. Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis. Hepatology 2016, 64: 1014-1016. PMID: 27388118, DOI: 10.1002/hep.28717.
- HIV, Aging, and Viral Coinfections: Taking the Long ViewTaddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.
- Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old manOoka K, Onyiuke I, Zhang X, Taddei TH. Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man. BMJ Case Reports 2016, 2016: bcr2016216649. PMID: 27591041, PMCID: PMC5020720, DOI: 10.1136/bcr-2016-216649.
- Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with CirrhosisKaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T, for the VOCAL Study Group. Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Digestive Diseases And Sciences 2016, 61: 3309-3320. PMID: 27405990, PMCID: PMC5067291, DOI: 10.1007/s10620-016-4239-6.
- Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma?Taddei T. Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma? Hepatology 2016, 63: 1078-1079. PMID: 26764271, DOI: 10.1002/hep.28452.
- Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare DatabaseKaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Knott A, Pedrosa M, Pocha C, Mehta R, Duggal M, Skanderson M, Valderrama A, Taddei TH, Group V. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology And Hepatology 2015, 13: 2333-2341.e6. PMID: 26188137, PMCID: PMC4655141, DOI: 10.1016/j.cgh.2015.07.010.
- Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and ChallengesVilarinho S, Taddei T. Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and Challenges. Current Treatment Options In Gastroenterology 2015, 13: 219-234. PMID: 25791207, DOI: 10.1007/s11938-015-0049-8.
- New frontier in liver cancer treatment: Oncolytic viral therapyVilarinho S, Taddei TH. New frontier in liver cancer treatment: Oncolytic viral therapy. Hepatology 2013, 59: 343-346. PMID: 23836532, PMCID: PMC4427510, DOI: 10.1002/hep.26605.
- Emphysematous Cholecystitis Resulting in Secondary Biliary Cirrhosis: A Rare Complication of Endoscopic Retrograde CholangiopancreatographyBari K, Aslanian HR, Pollak J, Reiner E, Salem RR, Taddei TH, Emre SH, Jamidar PA. Emphysematous Cholecystitis Resulting in Secondary Biliary Cirrhosis: A Rare Complication of Endoscopic Retrograde Cholangiopancreatography. ACG Case Reports Journal 2013, 1: 51-54. PMID: 26157820, PMCID: PMC4435262, DOI: 10.14309/crj.2013.18.
- INTRODUCTIONTaddei TH, Nathanson MH. INTRODUCTION. Journal Of Clinical Gastroenterology 2013, 47: s1. PMID: 23751799, DOI: 10.1097/mcg.0b013e3182936b7e.
- A Multidisciplinary ApproachTaddei TH. A Multidisciplinary Approach. Journal Of Clinical Gastroenterology 2013, 47: s27-s29. PMID: 23632364, DOI: 10.1097/mcg.0b013e31829331de.
- Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of MetabolismMistry PK, Taddei T, Dahl S, Rosenbloom BE. Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of Metabolism. Critical Reviews™ In Oncogenesis 2013, 18: 235-246. PMID: 23510066, PMCID: PMC4437216, DOI: 10.1615/critrevoncog.2013006145.
- EMR-linked cancer tracker facilitates lung and liver cancer care.Taddei T, Hunnibell L, DeLorenzo A, Rosa M, Connery D, Vogel D, Garla V, Taylor C, Rose M. EMR-linked cancer tracker facilitates lung and liver cancer care. Journal Of Clinical Oncology 2012, 30: 77-77. DOI: 10.1200/jco.2012.30.34_suppl.77.
- When should a hepatitis C‐positive ESRD patient receive a renal transplant?Kulkarni S, Taddei TH. When should a hepatitis C‐positive ESRD patient receive a renal transplant? Seminars In Dialysis 2011, 24: 438-439. PMID: 21801216, DOI: 10.1111/j.1525-139x.2011.00898.x.
- Systemic Therapy in Hepatocellular CarcinomaWrzesinski SH, Taddei TH, Strazzabosco M. Systemic Therapy in Hepatocellular Carcinoma. Clinics In Liver Disease 2011, 15: 423-441. PMID: 21689622, PMCID: PMC3758582, DOI: 10.1016/j.cld.2011.03.002.
- Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver TransplantationCimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center ExperienceCimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, Asch W, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. PMID: 21486624, DOI: 10.1016/j.transproceed.2011.02.033.
- Necrotizing Pancreatitis Complicated by Fistula and Upper Gastrointestinal HemorrhageSahakian AB, Krishnamoorthy S, Taddei TH. Necrotizing Pancreatitis Complicated by Fistula and Upper Gastrointestinal Hemorrhage. Clinical Gastroenterology And Hepatology 2011, 9: e66-e67. PMID: 21296188, DOI: 10.1016/j.cgh.2011.01.022.
- High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher diseaseTaddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. Journal Of Inherited Metabolic Disease 2010, 33: 291-300. PMID: 20354791, PMCID: PMC3008397, DOI: 10.1007/s10545-010-9070-1.
- The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patientsTaddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal Of Hematology 2009, 84: 208-214. PMID: 19260119, PMCID: PMC3008404, DOI: 10.1002/ajh.21362.
- Inherited metabolic disease of the liverTaddei T, Mistry P, Schilsky ML. Inherited metabolic disease of the liver. Current Opinion In Gastroenterology 2008, 24: 278-286. PMID: 18408455, DOI: 10.1097/mog.0b013e3282fcbc0f.
- Pseudocirrhosis in a pancreatic cancer patient with liver metastases: A case report of complete resolution of pseudocirrhosis with an early recognition and managementKang SP, Taddei T, McLennan B, Lacy J. Pseudocirrhosis in a pancreatic cancer patient with liver metastases: A case report of complete resolution of pseudocirrhosis with an early recognition and management. World Journal Of Gastroenterology 2008, 14: 1622-1624. PMID: 18330959, PMCID: PMC2693763, DOI: 10.3748/wjg.14.1622.
- Increased T-Cell Sinusoidal Lymphocytosis in Liver Biopsies in Patients With Chronic Hepatitis C and Mixed CryoglobulinemiaCarmack S, Taddei T, Robert ME, Mistry P, Jain D. Increased T-Cell Sinusoidal Lymphocytosis in Liver Biopsies in Patients With Chronic Hepatitis C and Mixed Cryoglobulinemia. The American Journal Of Gastroenterology 2007, 103: ajg200850138. PMID: 17970837, DOI: 10.1111/j.1572-0241.2007.01603.x.
- Hepatic Venous Pressure Gradient (HVPG), Serum Sodium (SNa), and Model of End-stage Liver Disease Score (MELD)Taddei TH, Strazzabosco M. Hepatic Venous Pressure Gradient (HVPG), Serum Sodium (SNa), and Model of End-stage Liver Disease Score (MELD). Journal Of Clinical Gastroenterology 2007, 41: 641-643. PMID: 17667045, DOI: 10.1097/mcg.0b013e318051741d.
- Impact of body mass index on graft failure and overall survival following liver transplant*Rustgi VK, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH. Impact of body mass index on graft failure and overall survival following liver transplant*. Clinical Transplantation 2004, 18: 634-637. PMID: 15516235, DOI: 10.1111/j.1399-0012.2004.00141.x.
- THE EFFICACY OF WEIGHT REDUCTION IN NONALCOHOLIC FATTY LIVER DISEASETaddei T, Younossi Z. THE EFFICACY OF WEIGHT REDUCTION IN NONALCOHOLIC FATTY LIVER DISEASE. Evidence-Based Gastroenterology 2004, 5: 96-97. DOI: 10.1097/00132579-200408000-00012.